Navigation Links
Cell-based alternative to animal testing
Date:8/7/2011

European legislation restricts animal testing within the pharmaceutical and cosmetic industries and companies are increasingly looking at alternative systems to ensure that their products are safe to use. Research published in BioMed Central's open access journal BMC Genomics demonstrates that the response of laboratory grown human cells can now be used to classify chemicals as sensitizing, or non-sensitizing, and can even predict the strength of allergic response, so providing an alternative to animal testing.

Allergic contact dermatitis can result in itching and eczema and is often due to repeated exposure to chemicals at work or in everyday life such as machine oil, detergents, soaps, and cosmetics. Unless the source of the sensitizing chemical is found the resulting rashes can be an ongoing source of misery for the sufferer. The 2009, 7th Amendment to the Cosmetic Directive bans testing of cosmetic products and ingredients on animals meaning that there is currently no way of ensuring new products are hypoallergenic.

Researchers from Lund University in Sweden used genome-wide profiling to measure the response of a human myeloid leukemia cell line to known chemicals. From this they defined a 'biomarker signature' of 200 genes, which could accurately discriminate between sensitizing and non-sensitizing chemicals. By comparing this signature with the known action of these chemicals they were also able to use this system to predict sensitizing potency.

Prof Borrebaeck said, "REACH (Registration, Evaluation, and Authorization of Chemicals) regulation requires that all new and existing chemicals within the European Union are tested for safety. The number of chemicals this includes is over 30,000 and is increasing all the time. Our lab-based alternative to animal testing, although in an early stage of production, is faster, out-performs present alternatives, and, because the cells are human in origin, is more relevant. It provides a way of ensuring the continued safety of consumers and users and, by identifying chemicals and products with low immunogenicity, reducing the suffering due to eczema."


'/>"/>

Contact: Dr. Hilary Glover
hilary.glover@biomedcentral.com
44-020-319-22370
BioMed Central
Source:Eurekalert

Related biology technology :

1. Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
2. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
3. O2h and Hypoxium Announce an Agreement to Offer Hypoxiums Specialised In Vitro, Cell-Based Oncology Assays via O2hs Biology Affiliate Program
4. Stemgent, CellDesign Sign Co-Exclusive Marketing Agreement on Stem Cell-Based Adipocyte Research Products
5. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
6. MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery
7. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
8. Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope
9. Reportlinker Adds Three Alternative Scenarios of the Future In Vitro Diagnostics Market through 2018
10. Qteros Management to Present at Alternative Energy Investment Banking Conferences
11. QuickExtenderPro.com Penis Extender Device Engineered for Quick, Safe and Effective Alternative to Penis Enlargement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017  Neogen Corporation (NASDAQ: ... terminated its agreement with SenesTech Incorporated (NASDAQ: ... a rodenticide being developed by SenesTech. The two firms ... time when the SenesTech product was approved by the ... approval provided that the product could only be used ...
(Date:1/24/2017)... and DURHAM, N.C. , ... IRB in customer service and technology, announces that ... the organization as Biosafety Officer. In ... leadership to develop and manage a forthcoming institutional biosafety ... for research organizations navigating the IBC landscape. The new ...
(Date:1/24/2017)... 2017  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... medicine, today announced positive efficacy results from the ... showed additional motor function improvement at 6-months and ... in AIS-A patients with complete cervical spinal cord ... motor function is critically important to patients with ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... waist circumference, and increased serum leptin levels had a positive association with increased ... The study published in the International Neurourology Journal involved 571 Korean men ...
Breaking Biology Technology:
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
Breaking Biology News(10 mins):